CAS: 62288-83-9; Desmopressin

该化合物是天然激素血管抑制素的合成类比,主要用于治疗糖尿病的胰岛素和夜阴素. 它有效地减少了过度的尿液生产和夜间尿液,提供了有针对性的治疗解决方案. 关键优势包括其强大的抗亚尿性行动,迅速产生效果以及最小的系统性副作用,这使得它成为管理这些状况的首选选择.

结构式图片

上下游产品

acetic acid

合成工艺路线路线简述

    海关参考信息

    专利信息


    专利号:EP-0412508-B1
    优先权日:1989-08-07
    标 题:Analogues of vasopressin, their preparation and pharmaceutical use
    发明人:PROCHAZKA ZDENKO; BLAHA IVO; ZERTOVA MIROSLAVA; SLANINOVA JIRINA; VELEK JIRI; SKOPKOVA JANA; LEBL MICHAL; BARTH TOMISLAV; MALETINSKA LENKA; VILHARDT HANS
    权利人:CESKOSLOVENSKA AKADEMIE VED
    摘要:The invention relates to analogues of 8-D-homoarginine-vasopressin of the general formula in which the meanings are: X L-O-methyltyrosine L-p-ethylphenylalanine D-p-ethylphenylalanine L-p-methylphenylalanine or D-p-methylphenylalanine and R cysteine or beta -mercaptopropionic acid to a process for the preparation thereof by solid-phase synthesis and to the pharmaceutical use thereof. The analogues of vasopressin have a selectively increased affinity for uterine oxytocin receptors, where they have an antagonistic action to oxytocin. The analogues of deaminovasopressin furthermore have a significantly reduced antidiuretic activity compared with [8-D-arginine]-deaminovasopressin.

    专利号:US-2023047961-A1
    优先权日:2019-12-03
    标 题 :The cholesterol-syntesis intermediates for treatment demyelinating disorders
    发明人:BERGHOFF STEFAN; SAHER GESINE
    权利人:MAX PLANCK GESELLSCHAFT
    摘要:The present invention relates to a cholesterol-synthesis intermediate as pharmaceutically active agent and/or pharmaceutical composition comprising the cholesterol-synthesis intermediate optionally together with one or two further pharmaceutically active agent(s) for use in the prophylaxis and/or treatment of demyelinating disorders/diseases, in particular multiple sclerosis.
    济南大象药物化学
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.eosmedchem.com
    电话: 0086 (531) 6990-5422, +86 18354147588👤
    📞济南大象药物化学 ⚠️参考联系方式

    销售电话:0086 (531) 6990-5422, +86 18354147588
    邮箱:info@eosmedchem.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Malve H, Goswami P, Asalkar A, More D. Role of Desmopressin in Bleeding Disorders: What Indian Physicians Need to Know? J Assoc Physicians India. 2025 Jan;73(1):58-60. doi: 10.59556/japi.73.0796. 31(1):8-16. doi: 10.18787/jr.2024.00007. Epub 2024 Mar 31.
    3: Everaert K, Holm-Larsen T, Bou Kheir G, Rottey S, Weiss JP, Vande Walle J, Kabarriti AE, Dossche L, Hervé F, Spinoit AF, Nørgaard JP, Juul KV. Potential clinical applications of current and future oral forms of desmopressin (Review). Exp Ther Med. 2024 May 29;28(2):303. doi: 10.3892/etm.2024.12592.
    4: Shahzad F, Ahmed U, Muhammad A, Shahzad F, Naufil SI, Sukkari MW, Kamran AB, Murtaza S, Khalid MB, Shabbir H, Saeed S. Safety and efficacy of desmopressin (DDAVP) in preventing hematoma expansion in intracranial hemorrhage associated with antiplatelet drugs use: A systematic review and metaanalysis. Brain Behav. 2024 May;14(5):e3540. doi: 10.1002/brb3.3540.

    合成参考文献


    参考文献:10.1124/mol.119.115964
    摘要:Lee TD, Lee OW, Brimacombe KR, Chen L, Guha R, Lusvarghi S, Tebase BG, Klumpp-Thomas C, Robey RW, Ambudkar SV, Shen M, Gottesman MM, Hall MD. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular Pharmacology. 2019 Nov;96(5):629–40. doi: 10.1124/mol.119.115964.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知